- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.05. | Medicenna Therapeutics Corp: Medicenna presents preclinical MDNA113 data at meeting | 1 | Stockwatch | ||
| 29.04. | Medicenna Therapeutics Corp: Medicenna's MDNA11 showing acceptable safety profile | 1 | Stockwatch | ||
| 29.04. | Medicenna Therapeutics has "elegant science", Research Capital says | 2 | Cantech Letter | ||
| 22.04. | Stocks in Play: Medicenna Therapeutics Corp. | 2 | Baystreet.ca | ||
| 26.03. | Medicenna Therapeutics Corp: Medicenna to present MDNA11 update at AACR | 1 | Stockwatch | ||
| 26.03. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 25.02. | Medicenna Therapeutics Corp: Medicenna talks MDNA11 Ability-1 study data | 1 | Stockwatch | ||
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.02. | Medicenna Therapeutics Corp.: Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones | 142 | GlobeNewswire (Europe) | - Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck's (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1... ► Artikel lesen | |
| 05.02. | Stocks in Play: Medicenna Therapeutics Corp | - | Baystreet.ca | ||
| 13.12.24 | Medicenna Therapeutics Corp.: Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS) | 1 | GlobeNewswire (USA) | ||
| 05.12.24 | Medicenna Therapeutics Corp.: Medicenna Provides Clinical Update and Announces First Complete Response in MDNA11 in Combination with KEYTRUDA (pembrolizumab) Dose Escalation Arm of the ABILITY-1 Study | 142 | GlobeNewswire (Europe) | 70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck's (known as MSD outside of the US and Canada)... ► Artikel lesen | |
| 15.11.24 | Medicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update | 182 | GlobeNewswire (Europe) | MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression... ► Artikel lesen | |
| 11.11.24 | Medicenna Therapeutics Corp.: Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA (pembrolizumab) at the ... | 155 | GlobeNewswire (Europe) | Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression with... ► Artikel lesen | |
| 08.11.24 | Medicenna Therapeutics Corp.: Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) | 204 | GlobeNewswire (Europe) | MDNA113 is a novel IL-13Ra2 tumor-targeted and "masked" BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor microenvironment... ► Artikel lesen | |
| 15.10.24 | OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX | 133 | GlobeNewswire (Europe) | NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna Therapeutics... ► Artikel lesen | |
| 26.09.24 | Medicenna Therapeutics Corp.: Medicenna Announces Results of Annual Meeting of Shareholders | 191 | GlobeNewswire (Europe) | TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the... ► Artikel lesen | |
| 27.06.24 | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights | 211 | GlobeNewswire (Europe) | Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity... ► Artikel lesen | |
| 26.06.24 | Medicenna Therapeutics Corp.: Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe | 442 | GlobeNewswire (Europe) | - ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA®... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
| TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
| BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
| VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
| JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
| EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
| 89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |
Das Unternehmen MEDICENNA THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.